In vitro killing of multidrug/extensively drug-resistant Pseudomonas aeruginosa by fosfomycin alone or in combination with antipseudomonal antibiotics. 2023

Mia Slade-Vitković, and Branka Bedenić, and Luka Bielen, and Ivanka Batarilo, and Sara Kibel, and Gordana Maravić-Vlahoviček
Croatian Institute for Transfusion Medicine, Zagreb, Croatia.

Pseudomonas aeruginosa is a leading cause of nosocomial infections. Given the constant rise in resistance, adequate therapy is increasingly demanding. Fosfomycin recently became an appealing treatment option of bacterial infections due to multidrug-resistant bacteria (MDR). So far, fosfomycin synergy with other antibiotics has been assessed in studies, but only a limited number focused on MDR P. aeruginosa and on the effect of these combinations on the duration of the postantibiotic effect (PAE). We investigated synergy of fosfomycin with an array of antipseudomonal antibiotics using gradient diffusion strip cross method and time-kill method, and their effect on the duration of PAE against 51 variously resistant P. aeruginosa isolates. The highest rate of synergy was observed for combination with ceftazidime (23.4%) and gentamicin (19.1%). The PAE of antibiotic combinations was superior to that of the drugs alone. Our findings indicate that fosfomycin combination therapy may be a valuable treatment alternative.

UI MeSH Term Description Entries
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D002442 Ceftazidime Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime Anhydrous,Ceftazidime Pentahydrate,Fortaz,Fortum,GR-20263,LY-139381,Pyridinium, 1-((7-(((2-amino-4-thiazolyl)((1-carboxy-1-methylethoxy)imino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, pentahydrate, (6R-(6alpha,7beta(Z)))-,Tazidime,GR 20263,GR20263,LY 139381,LY139381
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D005578 Fosfomycin An antibiotic produced by Streptomyces fradiae. Phosphonomycin,Fosfomycin Trometamol Salt,Fosfomycin Tromethamine,Monuril,Phosphomycin,Tromethamine, Fosfomycin
D005839 Gentamicins A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS. Gentamicin Sulfate (USP),Gentamycin,G-Myticin,Garamycin,Gentacycol,Gentamicin,Gentamicin Sulfate,Gentamycins,Gentavet,Genticin,G Myticin,GMyticin,Sulfate, Gentamicin
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D024901 Drug Resistance, Multiple, Bacterial The ability of bacteria to resist or to become tolerant to several structurally and functionally distinct drugs simultaneously. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Drug Resistance, Extensive, Bacterial,Drug Resistance, Extensively, Bacterial,Extensive Antibacterial Drug Resistance,Extensively Antibacterial Drug Resistance,Multidrug Resistance, Bacterial,Multiple Antibacterial Drug Resistance,Bacterial Multidrug Resistance,Bacterial Multidrug Resistances,Resistance, Bacterial Multidrug

Related Publications

Mia Slade-Vitković, and Branka Bedenić, and Luka Bielen, and Ivanka Batarilo, and Sara Kibel, and Gordana Maravić-Vlahoviček
November 1999, The Journal of antimicrobial chemotherapy,
Mia Slade-Vitković, and Branka Bedenić, and Luka Bielen, and Ivanka Batarilo, and Sara Kibel, and Gordana Maravić-Vlahoviček
June 2018, Antimicrobial agents and chemotherapy,
Mia Slade-Vitković, and Branka Bedenić, and Luka Bielen, and Ivanka Batarilo, and Sara Kibel, and Gordana Maravić-Vlahoviček
April 2016, Enfermedades infecciosas y microbiologia clinica,
Mia Slade-Vitković, and Branka Bedenić, and Luka Bielen, and Ivanka Batarilo, and Sara Kibel, and Gordana Maravić-Vlahoviček
December 2020, Antibiotics (Basel, Switzerland),
Mia Slade-Vitković, and Branka Bedenić, and Luka Bielen, and Ivanka Batarilo, and Sara Kibel, and Gordana Maravić-Vlahoviček
February 1995, Antimicrobial agents and chemotherapy,
Mia Slade-Vitković, and Branka Bedenić, and Luka Bielen, and Ivanka Batarilo, and Sara Kibel, and Gordana Maravić-Vlahoviček
December 2007, International journal of antimicrobial agents,
Mia Slade-Vitković, and Branka Bedenić, and Luka Bielen, and Ivanka Batarilo, and Sara Kibel, and Gordana Maravić-Vlahoviček
September 2019, Clinical microbiology reviews,
Mia Slade-Vitković, and Branka Bedenić, and Luka Bielen, and Ivanka Batarilo, and Sara Kibel, and Gordana Maravić-Vlahoviček
January 2016, Polish journal of microbiology,
Mia Slade-Vitković, and Branka Bedenić, and Luka Bielen, and Ivanka Batarilo, and Sara Kibel, and Gordana Maravić-Vlahoviček
July 2019, The Journal of infectious diseases,
Mia Slade-Vitković, and Branka Bedenić, and Luka Bielen, and Ivanka Batarilo, and Sara Kibel, and Gordana Maravić-Vlahoviček
March 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Copied contents to your clipboard!